



Curriculum Vitae

Europass

Informazioni personali

Nome/ Cognome

Samantha Pasca

Esperienza professionale

Date	01/02/204 - in corso
Lavoro o posizione ricoperti	Dirigente Medico
Principali attività e responsabilità	Medico
Nome e indirizzo del datore di lavoro	UO Multizonale Immunoematologia e Trasfusione – APSS di Trento
Tipo di attività o settore	Attività clinico-assistenziale
Date	Da 02/2022 a 10/2022
Lavoro o posizione ricoperti	Internship
Principali attività e responsabilità	Gestione clinico-laboratoristica del paziente affetto da malattie della coagulazione
Nome e indirizzo del datore di lavoro	Centro Emofilia e Trombosi “Angelo Bianchi Bonomi” – Fondazione IRCCS Ca’ Granda – Ospedale Maggiore Policlinico (Milano)
Tipo di attività o settore	Attività clinico-assistenziale e di ricerca
Date	Da 05/2021 a 12/2021
Lavoro o posizione ricoperti	Internship
Principali attività e responsabilità	Diagnostica microbiologica
Nome e indirizzo del datore di lavoro	Dipartimento di Patologia Clinica (U.O. Microbiologia) – Ospedale Ca’ Focello di Treviso
Tipo di attività o settore	Attività clinico-assistenziale
Date	Da 09/2016 a 31/01/2024)
Lavoro o posizione ricoperti	Borsa di Ricerca (fino a 09/2019) – Dottoranda di Ricerca (da 10/2019) – Specializzanda (da 01/2021)
Principali attività e responsabilità	Gestione trial clinici nell’ambito delle malattie emorragiche, congenite e acquisite Gestione del paziente con malattie emorragiche e tromboemboliche congenite e acquisite. Relazione con enti pubblici e privati per la progettazione e attuazione di studi clinici. Redazione pubblicazioni scientifiche di settore.
Nome e indirizzo del datore di lavoro	UOSD Coagulopatie (ora Medicina Generale)-DIMED, Università di Padova – U.O Medicina di Laboratorio -DSB, Università di Padova
Tipo di attività o settore	Attività clinico-assistenziale e di ricerca.
Date	Da 08/2008 a 08/2016
Lavoro o posizione ricoperti	Borsa di Ricerca
Principali attività e responsabilità	Gestione trial clinici nell’ambito delle malattie emorragiche e tromboemboliche, congenite e acquisite; Relazione con enti pubblici e privati per la progettazione e attuazione di studi clinici; Redazione pubblicazioni scientifiche di settore; Collaborazione alla redazione di protocolli aziendali e loro verifiche applicative; Progettazione e implementazione delle procedure aziendali finalizzate alle certificazioni JCI, ISO e agli accreditamenti istituzionali regionali, AICE, FCSA

Nome e indirizzo del datore di lavoro	SOS Malattie Emorragiche e Trombotiche - Dipartimento di Medicina Trasfusionale di AV Udinese, Azienda Ospedaliero-Universitaria "S. Maria della Misericordia" di Udine
Tipo di attività o settore	Ricerca clinica e sperimentale
Date	2006 - 03/2008
Lavoro o posizione ricoperti	Informatore scientifico del farmaco
Principali attività e responsabilità	ISF con competenze principalmente in ambito cardiologico, ortopedico, internistico e reumatologico; Attività di coordinamento con le altre linee territoriali; Attività di coordinamento tra direzione medica e sperimentatori per lo sviluppo di studi clinici.
Nome e indirizzo del datore di lavoro	Bristol Myers Squibb Srl
Tipo di attività o settore	Farmaceutico
Date	2002/2005
Lavoro o posizione ricoperti	Informatore scientifico del farmaco
Principali attività e responsabilità	ISF con competenze principalmente in ambito pediatrico, ginecologico, internistico e psichiatrico; Attività di coordinamento con le altre linee territoriali
Nome e indirizzo del datore di lavoro	Laboratori Baldacci S.p.A.
Tipo di attività o settore	Farmaceutico
Date	2000/2002
Lavoro o posizione ricoperti	Biologa Borsista
Principali attività e responsabilità	Raccolta, processazione e conservazione cellule staminali ematopoietiche; Gestione di registri e studi riguardanti il trapianto di midollo osseo; Attività di coordinamento tra la U.O. Medicina Trasfusionale e la Clinica Ematologica; produzie e utilizzo concentrati di gel piastrinico da PRP autologo e e omologo
Nome e indirizzo del datore di lavoro	Dipartimento per il Trapianto di Midollo Osseo, U.O. Medicina Trasfusionale, Azienda Ospedaliero-Universitaria "S. Maria della Misericordia" di Udine
Tipo di attività o settore	Ricerca Clinica
Date	1999/2000
Lavoro o posizione ricoperti	Biologa Borsista
Principali attività e responsabilità	Analisi virale, in particolare: HCV, HBV, HIV; Analisi Biomolecolare e genetiche, in particolare: Mutazione fattori della coagulazione, Test per attribuzione di paternità, Valutazione del Chimerismo post-trapianto di cellule staminali ematopoietiche; Ricerca clinica nell'ambito della Biologia Molecolare
Nome e indirizzo del datore di lavoro	Laboratorio di Analisi Virale e Biologia Molecolare, U.O. Medicina Trasfusionale, Azienda Ospedaliero-Universitaria "S. Maria della Misericordia" di Udine
Tipo di attività o settore	Ricerca Clinica
Istruzione e formazione	
Titolo della qualifica rilasciata	Specializzazione in Patologia Clinica e Biochimica Clinica
Nome e tipo d'organizzazione erogatrice dell'istruzione e formazione	Università degli Studi di Padova
Livello nella classificazione nazionale o internazionale	PhD

Titolo della qualifica rilasciata	Dottorato di Ricerca Scienze Cliniche e Sperimentali (curriculum Scienze Ematologiche e Geriatriche)
Nome e tipo d'organizzazione erogatrice dell'istruzione e formazione	Università degli Studi di Padova
Livello nella classificazione nazionale o internazionale	PhD
Titolo della qualifica rilasciata	PhD in rare bleeding disorders (Acquired hemophilia A)
Nome e tipo d'organizzazione erogatrice dell'istruzione e formazione	Maastricht University (The Netherlands)
Livello nella classificazione nazionale o internazionale	PhD
Titolo della qualifica rilasciata	Laurea Magistrale a ciclo unico in Medicina e Chirurgia
Nome e tipo d'organizzazione erogatrice dell'istruzione e formazione	Università degli Studi di Udine
Livello nella classificazione nazionale o internazionale	Medicinae Doctor (MD)
Iscrizione Albo	Ordine dei Medici della provincia di Udine nr.6103
Titolo della qualifica rilasciata	Laurea Magistrale a ciclo unico in Scienze Biologiche, indirizzo Biomolecolare
Nome e tipo d'organizzazione erogatrice dell'istruzione e formazione	Università degli Studi di Trieste
Livello nella classificazione nazionale o internazionale	Master of Science (MSc), Molecular Biology
Titolo della qualifica rilasciata	Training Center in Trombosi (SISSET) – AOU di Piacenza, Novembre 2017
Nome e tipo d'organizzazione erogatrice dell'istruzione e formazione	Barts and the London School of Medicine and Dentistry - Londra
Livello nella classificazione nazionale o internazionale	Preceptorship in Haemophilia management (Settembre 2012 e Novembre 2014)
Titolo della qualifica rilasciata	Diploma di Maturità Scientifica
Nome e tipo d'organizzazione erogatrice dell'istruzione e formazione	Liceo Scientifico Statale "G. Marinelli" di Udine
Livello nella classificazione nazionale o internazionale	Diploma di Maturità Scientifica
Capacità e competenze personali	
Madrelingua(e)	Italiano
Altra(e) lingua(e)	1. Inglese 2. Francese

Autovalutazione

Livello europeo (*)

Lingua

Lingua

Comprensione				Parlato				Scritto	
Ascolto		Lettura		Interazione orale		Produzione orale			
1	B2		B2		B1		B1		B2
2	B2		B2		B2		B2		B2

Capacità e competenze tecniche

- Project Leader “International Registry on Hemophilia A/B Carriers” – ISTH
- Membro ISTH (International Society Thrombosis and Hemostasis)
- Membro Siset (Società Italiana per lo Studio dell’Emostasi e della Trombosi)
- Membro SiBioC (Società Italiana di Biochimica Clinica e Biologia Molecolare)
- Membro AICE (Associazione Italiana Centri Emofilia)
- Membro SIMTI (Società Italiana di Medicina Trasfusionale e Immunoematologia)
- Componente commissione AICE-Associazioni e fino a 01/2023 delle commissioni Farmacocinetica e MEC-donna AICE
- Iscritta ai sottocomitati “Scientific and Standardization Committee dell’ISTH”: 1) Factor VIII, Factor IX and rare coagulation disorders; 2) Control of anticoagulation; 3) Women’s Health Issues in Thrombosis and Hemostasis
- Relatore convegni medico scientifici ambito trombosi ed emostasi
- Da gennaio 2011 ruolo di Reviewer per le riviste scientifiche di settore “Clinical and Applied Thrombosis/Hemostasis”, “Haemophilia”, “British Medical Journal”, “Expert Opinions on Orphan Drugs”, “Thrombosis Research” e “Journal of Hematology & Transfusion”, “Expert Review of Hematology” e “Drugs”, “Therapeutic Advances in Hematology” e “Expert Opinion on Biology Therapy”, “Current Medical Research & Opinion”, “Journal of Medical Economics”
- Corso di metodologia della ricerca clinica convenzionale e delle malattie rare Lucca 08-09-10 maggio 2014
- Collaboratrice della rivista “EX” dal maggio 2017
- Corso di Public Speaking, Udine dicembre 2010/gennaio 2011
- Corso di Statistica Medica e Medical Writing, Peschiera Borromeo (MI) 17-18 settembre 2010

Pubblicazioni scientifiche

1. Bleeding episodes in patients with hemophilia B receiving prophylactic factor IX treatment: a systematic review and meta-analysis Franchini M; Pasca S, Mengoli C; Focosi D, Mannucci PM. Accepted **Haemophilia** Jan 2025
2. Acquired Hemophilia A after SARS-CoV-2 Immunization: A Narrative Review of a Rare Side Effect Castelli R, Gidaro A, Manetti R, Castiglia P, Delitala AP, Mannucci PM, Pasca S. **Vaccines (Basel)** 2024 Jun 25;12(7):709
3. Specific serum biomarkers to assess the bone health in a group of hemophilia A carriers: data from the CAR.BONE Study. Pasca S, Giordano M, Faggian D, Basso D. **Thromb Res** 2024 Jan;233:200-202
4. Personalized therapy with myPKfit device: a real-world cost-effectiveness analysis in haemophilia A patients. Antonazzo CI, Cortesi PA, Zanon E, Pasca S, Morfini M, Santoro C, De Cristofaro R, Di Minno G, Mantovani LG. **Medicina (Kaunas)** 2023 Dec 24; 60 (1):34

5. Joint dysfunction as a cause of spontaneous and subclinical bleeding in infants with hemophilia. Boccalandro EA, Pasca S, Begnozzi V, Gualtierotti R. **J Clin Med** 2023 Oct 22; 12 (20): 6672
6. Bilirubin-induced color interference on prothrombin time and activated partial thromboplastin time tests assessed in patients with liver disease. Scalabrino E, Faioni EM, Clerici M, Avarello I, Capecci M, Pasca S, Peyvandi F, Tripodi A. **Clin Chem and Lab Res**, 23 Jun 21
7. Emicizumab in acquired hemophilia A: pros and cons of a new approach to the prevention and treatment of bleeding. Pasca S, Zanon E, Mannucci PM, Peyvandi F. **Blood Trans** 2023 Nov 7; 21 (6): 549-556
8. Very high risk of intracranial hemorrhage and severe outcomes in adult patients with mild hemophilia: sub-analysis of the EMO.REC Registry. Pasca S, Linari S, Tagliaferri A, Santoro C, Zanon E; for the EMO.REC Study group. **Thromb Res** 2023 Jan; 221: 35-36
9. Updates on Novel Non-Replacement Drugs for Hemophilia. Gualtierotti R, Pasca S, Ciavarella A, Arcudi S, Giachi A, Garagiola I, Suffritti C, Siboni SM, Peyvandi F. **Pharmaceuticals** (Basel) 2022 Sep 23; 15 (10):1183
10. Concizumab as a subcutaneous prophylactic treatment option for patients with hemophilia A or B: a review of the evidence and patient's perspectives. Pasca S. **J Blood Med** 2022 Apr 16;13:191-199
11. Diagnosis and treatment of chronic synovitis in patients with haemophilia: consensus statements from the Italian Association of Haemophilia Centres. Di Minno MND, Napolitano M, Giuffrida AC, et al. **Br J Haematol** 2022 Feb;196 (4): 871-83
12. A woman hemophilia carrier with life-threatening esophageal varices and a severe hemophiliac male: a comparison between two different case reports and a brief description of literature. Pasca S, Fasolato S, Polese L, Zanon E. **J J Gastro**, Vol.2 April 2022
13. Intracranial haemorrhage in haemophilia patients is still an open issue: the final results of 10-yr Italian (AICE) EMO.REC Registry. Zanon E, Pasca S, Demartis F, Tagliaferri T, Santoro C, Cantori I, Molinari AC, Biasoli C, Coppola A, Castanan G, Linari S, Luciani M, Sottolotta G, Ricca I, Pollio B, Borchellini A, Peyvandi F. **J Clin Med** 2022 Apr 1; 11 (7):1969
14. A multicenter, real-world experience with recombinant FXIII for the treatment of patients with FXIII deficiency: from pharmacokinetics to clinics – The Italian FXIII Study. Zanon E, Pasca S, Sottolotta G, Molinari AC, Banov L, Ferretti A, Di Gregorio P, Pollio B, Siboni SM, Palla R, Peyvandi F, Pizzuti M, Notarangelo LD, Simioni P, Cojutti P, Biasoli C, Pea F. **Blood Transfus** 2023 Jul; 21 (4): 350-355
15. Real-world clinical outcomes and replacement factor VIII consumption in patients with haemophilia A in Italy: a comparison between prophylaxis pre and post Octocog alfa (Kovaltry®). Cortesi PA, Di Minno G, Zanon E, Giuffrida G, Santoro RC, Marino R, D'Angiolella LS, Antonazzo IC, Squassabia G, Clemente F, Di Laura D, Cimino E, Pasca S, Nicolosi D, Mantovani LG. **J Clin Med**, 2022 Jun 15;11 (12): 3434
16. Albumin-fusion recombinant FIX in the management of people with hemophilia B: an evidence-based review. Pasca S, Zanon E. **Drug Des Devel Ther**, 2022 Sep 15;16:3109-3116
17. The evolution of physiotherapy in the multidisciplinary management of persons with haemophilia (PWH): a scoping review. Boccalandro EA, Begnozzi V, Garofalo S, Pasca S, Peyvandi F. **Haemophilia**, 2022 Sep 27
18. The pharmacokinetics of recombinant FXIII (catridecag) from the MENTOR™2 trial to a Real-World study: a head-to-head comparison. Pasca S, Cojutti PG, Pea F, Zanon E. **J Thromb Thrombolysis**, 2022 Nov; 54 (4): 593-596
19. Comparison among three different bleeding scores and the Thrombin Generation Assay to assess the haemorrhagic phenotype in patients with FVII deficiency. Pasca S, Santoro C, Ambaglio C, Napolitano M, Milan M, Natali L, Nannizzi S, Mori F, Simioni P, Zanon E. **BTBV**, May 2022, Vol. 2
20. Real-Life Population Pharmacokinetics of Recombinant Factor XIII and Dosing Considerations for Preventing the Risk of Bleeding in Patients with FXIII Congenital Deficiency. Cojutti PG, Zanon E, Pasca S, Pea F; Italian FXIII Study Group. **Clin Pharmacokinet** 2021 Oct
21. rFVIII single-chain in an Italian population of hemophilia A patients: the Veneto experience E. Zanon, S. Pasca, P. Radossi, E. Bonetti, A. C. Giuffrida, A. Tosetto. **Hemonline** 2021
22. Rehabilitation management of a triceps surae muscle injury in a young male with haemophilia A and high-titre inhibitors. Frizziero A, Finotti P, Costantino C, Pasca S, Zanon E. **Acta Biomed**. 2021 Apr 30; 92 (S1): e2021118
23. Addressing the impact of SARS-CoV-2 infection in persons with congenital bleeding disorders: The Italian MECCOVID-19 study. Coluccia A, Marchesini E, Giuffrida AC, Rivolta GF, Ricca I, Zanon E, Luciani M, De Cristofaro R, Coppola A, Rocino A; AICE MECCOVID-19 Study Group. **Haemophilia** 2021 May 13
24. ABO Blood Group and Inhibitor Risk in Severe Hemophilia A Patients: A Study from the Italian Association of Hemophilia Centers.

Franchini M, Coppola A, Santoro C, De Cristofaro R, Barillari G, Giordano P, Gresele P, Lassandro G, Napolitano M, Lucchini G, Luciani M, Ferretti A, Baldacci E, Riccardi F, Santoro RC, Pasca S, Zanon E, Tagliaferri A.

Semin Thromb Hemost. 2021 Feb;47(1):84-89

25. Regenerative Surgery with Dental Implant Rehabilitation in a Haemophiliac Patient. Bacci C, Cerrato A, Zanette G, Pasca S, Zanon E. **TH Open.** 2021 Mar 16;5(1):e104-e106
26. Lights and shadows of the new therapies for haemophilia treatment in the Covid-19 era. Pasca S, Zanon E. **Blood Transfus** 2020 Sep, 18
27. Haemophilia A/B carriers: haemorrhagic burden of disease and open issues. Pasca S, Zanon E. **Blood Transfus** 2020 Nov;18(6):496-497.
28. Treatment With Efmorotocog Alfa (Elocta®) in Hemophilia: A Case Series. Zanon E, Tosetto A, Radossi P, Pasca S, Bonetti E, Giuffrida AC, Cesaro S. **Clin Management Issues**, Oct 2020.
29. How haemophilia A impacts Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-Cov-2) treatment: a case report. Zanon E, Pasca S, Campello E, Spiezia L, Vettor R, Simioni P. **J Thromb Thrombolysis** 2020 Nov;50(4):795-798.
30. Acquired haemophilia A, concomitant acute myocardial infarction and urgent major surgery: how to successfully treat a critical patient with rFVIII (Obizur®). Zanon E, Pasca S, Spiezia L, Poletto F, Gherardi S, Simioni P. **Thromb Res** 2020 Nov;195:125-127
31. Susoctocog-alfa (Obizur®) in the treatment of nine elderly patients with acquired haemophilia A: an Italian multicentre real life experience Zanon E, Pasca S, Borchellini A, Lodigiani C, Molinari AC, Moscatelli P, Ambaglio C, Preti PS, Simioni P. **Blood Transfus** 2020 Jul;18(4):312-321
32. Savings without changing: how to use the *MyPKfit*® device to improve treatment strategies in a cohort of patients with haemophilia A. Pasca S, Zanon E. **Thromb Res** 2019 Nov;183:1-3
33. Consensus statements on vaccination in patients with haemophilia – Results from the Italian haemophilia and vaccination (HEVA) project. Santagostino E, Riva A, Cesaro S, Esposito S, Matino D, Mazzucchelli RI, Molinari AC, Mura R, Notarangelo D, Tagliaferri A, Di Minno G, Clerici M, the HEVA Study Group. **Haemophilia** 2019 Jul;25(4):656-667
34. Physical activity improved by adherence to prophylaxis in an Italian population of children, adolescents and adults with severe haemophilia A: the SHAPE Study. Zanon E, Tagliaferri A, Pasca S, Ettore C, Notarangelo L, Biasoli C, Aru B, Linari S, Rocino A, Gagliano F, Di Minno G, Gamba G, Santoro R, Schinco P, Marietta M, Seuser A, von Mackensen S. **Blood Transfus** 2019 Jun 5: 1-6
35. Immune Tolerance Induction with moroctocog-alpha (Refacto/Refcto AF) in a population of Italian haemophilia A patients and high-titre inhibitors: data from REF.IT Registry. Zanon E, Pasca S, Pollio B, Santagostino E, Linari S, Tagliaferri A, Santoro C, Rocino A, Marino R, Aru B, Borchellini A, Siragusa S, Coppola A. **Haemophilia** 2019 Nov;25(6):1003-1010
36. Spontaneous recurrent intracranial haemorrhage in a woman with type 2B von Willebrand disease: a clinical case and a brief literature review. Zanon E, Pasca S, Bertomoro A, Madari R, Simioni P. **Haemophilia** 2019 Jul;25(4): e282-e285
37. Intracranial haemorrhage in children and adults with haemophilia A and B: a literature review of the last 20 years. Zanon E, Pasca S. **Blood Transfus** 2019 Feb; 4: 1-7
38. Low dose of aPCC after the initial treatment in acquired hemophilia A is useful to reduce bleeding relapses: data from the FAIR Registry. Zanon E, Pasca S, Siragusa S, Napolitano M, Santoro C, Mameli L, Rocino A; for the *FAIR Study Group. **Thromb Res** 2019 Feb; 174:24-26
39. Tailored prophylaxis with rFXIII (NovoThirteen®) in a young girl with severe FXIII deficiency and previous cephalohematoma. Zanon E, Pasca S, Radu CM, Spiezia L, Simioni P. **Haemophilia** 2019 May; 25(3): e206-e208
40. Combined use of antifibrinolytics and activated prothrombin complex concentrate (aPCC) is not related to thromboembolic events in patients with acquired haemophilia A: data from FAIR Registry. Pasca S, Ambaglio C, Rocino A, Santoro C, Cantori I, Zanon E; for the *FAIR Study Group. **J Thromb Thrombolysis**, 2019 Jan;47(1):129-133
41. Music is a rainbow: effects of musictheray on haemophiliac children. Zanon E, Pasca S, Salmaso L, Macellari E. **Medico e Bambino**, Febbraio 2019
42. The sudden and unexpected appearance of inhibitors in a previously treated severe haemophilia B patient (PTP) after the switch to albutrepenonacog alpha. Zanon E, Pasca S, Simioni P. **Haemophilia**, 2018 Sep; 24(5) :e372-e375

43. Immune Tolerance (ITI) Rescue with turoctocog-alfa in a poor risk hemophilia a young-child with inhibitors: a history of a success. Zanon E, Milano M, Pasca S. **Blood Coagul Fibrinolysis**, 2018 Jul; 29(5): 465-466
44. Managing a rare brain tumor in haemophilia patient: the two-faces Janus of the coagulation side. Milano M, Pasca S, Sarolo L, Della Puppa A, Zanon E. **J Blood Res**, 2018 30 Jun
45. Can the plasmaderived play a role in the treatment of acquired haemophilia A at the time of the new drugs? Pasca S, De Angelis V, Milano M, Zanon E. **Blood Coagul Fibrinolysis**, 2018 Jul; 29(5): 417-422
46. Activated prothrombin concentrate (FEIBA®) in acquired hemophilia A: a large multicenter Italian study - the FAIR Registry. E Zanon, S Pasca, M Milano, C Santoro, G Gamba, C Ambaglio, S Siragusa, M Napolitano, A Rocino, I Cantori, A.B. Federici, L Mameli, G Giuffrida, A Falanga, C Lodigiani, R Santoro, MG Mazzucconi. **Br J Haematol**, 2019 Mar; 184 (5):853-5
47. Cerebrovascular diseases in hemophiliacs: a real, but underestimated risk. E.Zanon, M. Milan, L.Sarolo, S. Pasca. **Haemophilia**, 2018 Jan; 24(1): e3-e5
48. Clinical course of patients with symptomatic isolated superficial vein thrombosis: the ICARO follow-up study. Barco S, Pomero F, Di Minno MND, Tamborini Permuni E, Malato A, Pasca S, Barillari G, Fenoglio L, Siragusa S, Di Minno G, Ageno W, Dentali F. **J Thromb Haemost**. 2017 Sep 4.
49. PK-driven prophylaxis versus standard prophylaxis: when a tailored treatment might be a real and achievable cost-saving approach in children with severe hemophilia A. S. Pasca, M. Milano, L.Sarolo, E.Zanon, **Thromb Res**, Sep 157: 58-63
50. Cesarean surgery or vaginal delivery in a pregnant woman with homozygous FXI deficiency and FXI level <1%? This the question! Barillari G, Springolo F, Pasca S, Del Fabbro A, Marzoesoni D. **Minerva Ginecologica** 2016 Aug; 68 (4): 476-7
51. Infection as cause of immobility and occurrence of venous thromboembolism analysis of 1635 medical cases from the RIETE Registry, Frasson S, Gussoni G, Di Micco P, Barba R, Bertolotti L, Nunez MJ, Valero B, Samperiz AL, Rivas A Monreal M, RIETE Investigators. **J Thromb Thrombolysis** 2016 Apr; 12 (8); 1122-9
52. Intracranial hemorrhage recurrence on vitamin K antagonist: severity of the first episode and HASBLED score fail to identify high-risk patients from the CHIRON study. Poli D, Antonucci E, Dentali F, Testa S, Palareti G and the Italian Federation of Anticoagulation Clinics (FCSA). Accepted **Blood Coagul Fibrinolysis**, Feb 2016
53. Cancers in Patients with von Willebrand Disease: A Survey from the Italian Association of Haemophilia Centres. Franchini M, Di Perna C, Santoro C, Castaman G, Siboni SM, Zanon E, Linari S, Gresele P, Pasca S, Coppola A, Santoro R, Napolitano M, Ranalli P, Tagliaferri A; Italian Association of Haemophilia Centres. **Semin Thromb Hemost** 2016 Feb; 42(1):36-41
54. Trends in the Management and Outcomes of Acute Pulmonary Embolism: analysis from the RIETE Registry. Jiemenez D, de Miguel-Diez J, Guijarro R, Trujillo-Santos J, Otero R, Barba R, Muriel A, Meyer G, Yusen RD, Monreal M, RIETE Investigators, **J Am Coll Cardiol** 2016 Jan 19; 67 (2): 162-70
55. The management of acute venous thromboembolism in clinical practice-study rationale and protocol of the European PREFER in VTE Registry. Agnelli G, Gitt AK, Bauersachs R and PREFER study group. **Thrombosis Journal**, Dec 2015
56. Platelet count and major bleeding in patients receiving vitamin K antagonists for acute thromboembolism findings from real world clinical practice. Giorgi-Pierfranceschi M, Di Micco P, Cattabiani C, Guida A, Pagan B, Morales Mdel V, Salgado E Surinach JM, Tolosa C, Monreal M, RIETE Investigators. **Medicine (Baltimore)** 2015 Nov; 94 (47): e1915
57. Direct Oral Anticoagulants for Very Elderly People With Atrial Fibrillation: Efficacy and Safe Enough? Pasca S, Venturelli U, Bertone A, Barillari G. **Clin Appl Thromb Hemost**. 2015 Nov 30
58. A clinical score to rule out the concomitant presence of deep vein thrombosis in patients presenting with superficial vein thrombosis: The ICARO study. Pomero F, Di Minno MN, Tamburini Permuni E, Malato A, Pasca S, Barillari G, Fenoglio L, Siragusa S, Di Minno G, Ageno W, Dentali F. **Thromb Res**. 2015 Nov; 136(5):938-42.
59. The impact of disseminated intravascular coagulation on the outcome of cancer patients with venous thromboembolism. Spiezia L, Campello E, Trujillo-Santos J, Piovella C, Brenner B, Monreal M, Prandoni P; RIETE Investigators. **Blood Coagul Fibrinolysis**. 2015 Sep; 26(6):709-11

60. Long-term Clinical Outcomes of Splanchnic Vein Thrombosis: Results of an International Registry. Ageno W, Riva N, Schulman S, Beyer-Westendorf J, Bang SM, Senzolo M, Grandone E, Pasca S, Di Minno MN, Duce R, Malato A, Santoro R, Poli D, Verhamme P, Martinelli I, Kamphuisen P, Oh D, D'Amico E, Becattini C, De Stefano V, Vidili G, Vaccarino A, Nardo B, Di Nisio M, Dentali F. **JAMA Intern Med.** 2015 Sep;175(9):1474-80
61. Identification of Low-Risk Patients with Acute Symptomatic Pulmonary Embolism for Outpatient Therapy. Maestre A, Trujillo-Santos J, Riera-Mestre A, Jiménez D, Di Micco P, Bascuñana J, Vela JR, Peris L, Malfante PC, Monreal M; RIETE Investigators. **Ann Am Thorac Soc.** 2015 Aug;12(8):1122-9.
62. A RIETE Registry analysis of recurrent thromboembolism and hemorrhage in patients with catheter-related thrombosis. Baumann Kreuziger L, Cote L, Verhamme P, Greenberg S, Caprini J, Munoz FJ, Valle E, Monreal Bosch, RIETE Investigators. **J Vasc Surg Venous Lymphat Disord** 2015 Jul; 3 (3): 243-50
63. A prognostic score to identify low-risk outpatients with acute deep vein thrombosis in the upper extremity. Rosa-Salazar V, Trujillo-Santos J, Díaz Peromingo JA, Apollonio A, Sanz O, Malý R, Muñoz-Rodríguez FJ, Serrano JC, Soler S, Monreal M; RIETE Investigators. **J Thromb Haemost.** 2015 Jul;13(7):1274-8
64. Fatal events in cancer patients receiving anticoagulant therapy for venous thromboembolism. Farge D, Trujillo-Santos J, Debaudaud P, RIETE Investigators. **Medicine (USA),** Jul 2015
65. Long-Term Anticoagulant Therapy of Patients with Venous Thromboembolism. What Are the Practices? Mahé I, Sterpu R, Bertolotti L, López-Jiménez L, Mellado Joan M, Trujillo-Santos J, Ballaz A, Hernández Blasco LM, Marzoena PJ, Monreal M; RIETE Investigators. **PLoS One.** 2015 Jun 15;10(6):e0128741
66. The Italian START-Register on Anticoagulation with Focus on Atrial Fibrillation. Antonucci E, Poli D, Tosetto A, Pengo V, Tripodi A, Magrini N, Marongiu F, Palareti G; START-Register. **PLoS One.** 2015 Maggio 22;10(5):e0124719.
67. Recurrent venous thromboembolism in anticoagulated patients with cancer: management and short-term prognosis. Schulman S, Zondag M, Linkins L, Pasca S, Cheung YW, de Sancho M, Gallus A, Lecumberri R, Molnar S, Ageno W, Le Gal G, Falanga A, Hulegårdh E, Ranta S, Kamphuisen P, Debourdeau P, Rigamonti V, Ortel TL, Lee A. **J Thromb Haemost.** 2015 Jun;13(6):1010-8.
68. Safety of vitamin K antagonist treatment for splanchnic vein thrombosis: a multicenter cohort study. Riva N, Ageno W, Poli D, Testa S, Rupoli S, Santoro R, Lerede T, Piana A, Carpenedo M, Nicolini A, Ferrini PM, Tosetto A; Italian Federation of Anticoagulation Clinics (FCSA); Italian Federation of Anticoagulation Clinics FCSA. **J Thromb Haemost.** 2015 Jun;13(6):1019-27
69. Venous thromboembolism in patients immobilised at home. López-Reyes R, Nauffal D, Ballester M, Martín-Antorán JM, de Sousa MS, Riera-Mestre A, Ruiz-Ruiz J, Fernández-Capitán C, Uresandi F, Monreal M; RIETE investigators. **Eur Respir J.** 2015 Jun;45(6):1728-31.
70. Thrombophilic mutations as risk factor for retinal vein occlusion: a case-control study. Russo PD, Damante G, Pasca S, Turello M, Barillari G. **Clin Appl Thromb Hemost.** 2015 Maggio;21(4):373-7.
71. Duration of anticoagulation after venous thromboembolism in real world clinical practice. Ageno W, Samperiz A, Caballero R, Dentali F, Di Micco P, Prandoni P, Becattini C, Uresandi F, Verhamme P, Monreal M; RIETE investigators. **Thromb Res.** 2015 Apr;135(4):666-72
72. Fondaparinux in the initial and long-term treatment of venous thromboembolism. Pesavento R, Amitrano M, Trujillo-Santos J, Di Micco P, Mangiacapra S, Lopez-Jimenez L, Falgà CGarcia-Bragado F, Piovella C, Prandoni P, Monreal M, RIETE Investigators. **Thromb Res** 2015 Feb; 135 (4): 666-72
73. Gender differences in cancer patients with acute venous thromboembolism. Martín-Martos F, Trujillo-Santos J, Barrón M, Vela J, Javier Marzoena P, Braester A, Hij A, Hernández-Blasco L, Verhamme P, Manuel M; RIETE Investigators. **Thromb Res.** 2015 Feb;135 Suppl 1:S12-5.
74. A prognostic score to identify low-risk outpatients with acute deep vein thrombosis in the lower limbs. Trujillo-Santos J, Lozano F, Lorente MA, Adarraga D, Hirmerova J, Del Toro J, Mazzolai L, Barillari G, Barrón M, Monreal M; RIETE Investigators. **Am J Med.** 2015 Jan;128(1):90.e9-15
75. Sex differences in patients receiving anticoagulant therapy for venous thromboembolism. Blanco-Molina A, Enea I, Gadelha T, Tufano A, Bura-Riviere A, Di Micco P, Bounameaux H, González J, Villalta J, Monreal M; RIETE Investigators. **Medicine (Baltimore).** 2014 Oct;93(17):309-17

76. Outcomes in neurosurgical patients who develop venous thromboembolism: a review of the RIETE registry. Cote LP, Greenberg S, Caprini JA, Stone J, Arcelus JI, López-Jiménez L, Rosa V, Schellong S, Monreal M; RIETE Investigators. **Clin Appl Thromb Hemost.** 2014 Nov;20(8):772-8.
77. Safety of fondaparinux in the prevention of venous thromboembolism in elderly medical patients: results of a single-center, retrospective study. Silvestri F, Pasca S, Labombarda A, Barbi A, Desideri M, Guidi P, Rogato A, Zaramella M, Bergamo M, Ageno W, Barillari G. **Minerva Med.** 2014 Jun;105(3):221-8.
78. Home versus in-hospital treatment of outpatients with acute deep venous thrombosis of the lower limbs. Lozano F, Trujillo-Santos J, Barrón M, Gallego P, Babalis D, Santos M, Falgá C, Monreal M; RIETE Investigators. **J Vasc Surg.** 2014 Maggio;59(5):1362-7.
79. D-dimer levels and 90-day outcome in patients with acute pulmonary embolism with or without cancer. Maestre A, Trujillo-Santos J, Visoná A, Lobo JL, Grau E, Malý R, Duce R, Monreal M; RIETE Investigators. **Thromb Res.** 2014 Mar;133(3):384-9.
80. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. Hokusai-VTE Investigators, Büller HR, Décousus H, Grosso MA, Mercuri M, Middeldorp S, Prins MH, Raskob GE, Schellong SM, Schwocho L, Segers A, Shi M, Verhamme P, Wells P. **N Engl J Med.** 2013 Oct 10;369(15):1406-15
81. Dynamics of case-fatality rates of recurrent thromboembolism and major bleeding in patients treated for venous thromboembolism. Lecumberri R, Alfonso A, Jiménez D, Fernández Capitán C, Prandoni P, Wells PS, Vidal G, Barillari G, Monreal M; RIETE investigators. **Thromb Haemost.** 2013 Oct;110(4):834-43
82. Platelet count and outcome in patients with acute venous thromboembolism. Di Micco P, Ruiz-Giménez N, Nieto JA, Aujesky D, del Molino F, Valle R, Barrón M, Maestre A, Monreal M; RIETE investigators. **Thromb Haemost.** 2013 Nov;110(5):1025-34.
83. Pulmonary embolism and 3-month outcomes in 4036 patients with venous thromboembolism and chronic obstructive pulmonary disease: data from the RIETE registry. Bertoletti L, Quenet S, Laporte S, Sahuquillo JC, Conget F, Pedrajas JM, Martin M, Casado I, Riera-Mestre A, Monreal M; RIETE Investigators. **Respir Res.** 2013 Jul 18; 14: 75
84. Validation of a score for predicting fatal bleeding in patients receiving anticoagulation for venous thromboembolism. Nieto JA, Solano R, Trapero Iglesias N, Ruiz-Giménez N, Fernández-Capitán C, Valero B, Tiberio G, Bura-Riviere A, Monreal M; RIETE Investigators. **Thromb Res.** 2013
85. Low-molecular-weight or unfractionated heparin in venous thromboembolism: the influence of renal function. Trujillo-Santos J, Schellong S, Falga C, Zorrilla V, Gallego P, Barrón M, Monreal M; RIETE Investigators. **Am J Med.** 2013 Maggio;126(5):425-434.e1
86. Safety and efficacy of thromboprophylaxis with fondaparinux in elderly acutely ill medical patients with renal impairment: a retrospective single center study. Silvestri F, Pasca S, Labombarda A, Barbi A, Desideri M, Guidi P, Rogato A, Zaramella M, Bergamo M, Barillari G. **Italian J Med,** Maggio 2013
87. Factors associated with elevated pulmonary arterial pressure levels on the echocardiographic assessment in patients with prior pulmonary embolism. Otero R, Elías T, Jara L, Trujillo-Santos J, Bertoletti L, Nauffal D, Ruiz-Ruiz J, Blanco-Molina Á, Monreal M; RIETE investigators. **Thromb Res.** 2013 Maggio;131(5):e191-5.
88. When an optimal control of haemostasis is fundamental: a case report of patient with simultaneous acquired FVIII deficiency and venous thromboembolism. Pasca S, Barillari G. **Gazzetta Medica Italiana Archivio per le Scienze Mediche** 2013 Marzo;172(3):235-9
89. pdFVIII/VWF: an alternative treatment for old medical patient with acquired haemophilia A and systemic vascular diseases. Barillari G, Pasca S. **Transfus Apher Sci.** 2013 Feb;48(1):59-62
90. Usefulness of thrombophilia testing in venous thromboembolic disease: findings from the RIETE registry. Gabriel F, Portolés O, Labiós M, Rodríguez C, Cisneros E, Vela J, Nuñez M; RIETE Investigators. **Clin Appl Thromb Hemost.** 2013 Jan-Feb;19(1):42-7.
91. A clinical prognostic model for the identification of low-risk patients with acute symptomatic pulmonary embolism and active cancer. den Exter PL, Gómez V, Jiménez D, Trujillo-Santos J, Muriel A, Huisman MV, Monreal M; Registro Informatizado de la Enfermedad TromboEmbólica (RIETE) Investigators. **Chest.** 2013 Jan;143(1):138-45.
92. Haemophilia in children today (L'emofilia nel bambino di oggi). Giglia D, Pasca S, Barillari G. **Medico e bambino** 2012; 31: 632-8

93. Pregnancy-associated acquired haemophilia A: results from the European Acquired Haemophilia (EACH2) registry. Tengborn L, Baudo F, Huth-Kühne A, Knoebl P, Lévesque H, Marco P, Pellegrini F, Nemes L, Collins P; EACH2 registry contributors. **BJOG**. 2012 Nov;119(12):1529-37
94. Efficacy and safety of peripheral blood stem cell mobilization and collection: a single-center experience in 190 allogeneic donors. Rinaldi C, Savignano C, Pasca S, Sperotto A, Patriarca F, Isola M, Fanin R, De Angelis V. **Transfusion**. 2012 Nov;52(11):2387-94
95. Influence of recent immobilization and recent surgery on mortality in patients with pulmonary embolism. Nauffal D, Ballester M, Reyes RL, Jiménez D, Otero R, Quintavalla R, Monreal M; RIETE Investigators. **J Thromb Haemost**. 2012 Sep;10(9):1752-60.
96. Venous thromboembolism in immobilized patients with dementia. Findings from the RIETE registry. Nuñez MJ, Villalba JC, Cebrián E, Visoná A, Lopez-Jimenez L, Núñez M, Szwebel TA, Luque JM, Jaras MJ, Monreal M; RIETE Investigators. **Thromb Res**. 2012 Aug;130(2):173-7
97. Management of bleeding in acquired hemophilia A: results from the European Acquired Haemophilia (EACH2) Registry. Baudo F, Collins P, Huth-Kühne A, Lévesque H, Marco P, Nemes L, Pellegrini F, Tengborn L, Knoebl P; EACH2 registry contributors. **Blood**. 2012 Jul 5;120(1):39-46
98. Long-term outcomes of patients with cerebral vein thrombosis: a multicenter study. Dentali F, Poli D, Scoditti U, Di Minno MN, De Stefano V, Siragusa S, Kostal M, Palareti G, Sartori MT, Grandone E, Vedovati MC, Ageno W; CErebral VEin Thrombosis International Study Investigators, Falanga A, Lerede T, Bianchi M, Testa S, Witt D, McCool K, Bucherini E, Grifoni E, Coalizzo D, Benedetti R, Marietta M, Sessa M, Guaschino C, di Minno G, Tufano A, Barbar S, Malato A, Pini M, Castellini P, Barco S, Barone M, Paciaroni M, Alberti A, Agnelli G, Giorgi Pierfranceschi M, Dulicek P, Silingardi M, Federica L, Ghirarduzzi A, Tiraferri E, di Lazzaro V, Rossi E, Ciminello A, Pasca S, Barillari G, Rezoagli E, Galli M, Squizzato A, Tosetto A. **J Thromb Haemost**. 2012 Jul;10(7):1297-302
99. Immunosuppression for acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2). Collins P, Baudo F, Knoebl P, Lévesque H, Nemes L, Pellegrini F, Marco P, Tengborn L, Huth-Kühne A; EACH2 registry collaborators. **Blood**. 2012 Jul 5;120(1):47-55.
100. Aspirin for preventing the recurrence of venous thromboembolism. Becattini C, Agnelli G, Schenone A, Eichinger S, Bucherini E, Silingardi M, Bianchi M, Moia M, Ageno W, Vandelli MR, Grandone E, Prandoni P; WARFASA Investigators. **N Engl J Med**. 2012 Maggio 24;366(21):1959-67
101. Thrombolytic therapy and outcome of patients with an acute symptomatic pulmonary embolism. Riera-Mestre A, Jiménez D, Muriel A, Lobo JL, Moores L, Yusen RD, Casado I, Nauffal D, Oribe M, Monreal M; RIETE investigators. **J Thromb Haemost**. 2012 Maggio;10(5):751-9.
102. The international factor IX treatment network survey. Berntorp E, Shapiro AD, Waters J, Astermark J; International Factor IX Treatment Network. **Haemophilia**. 2012 Maggio;18(3): e60-2.
103. Unsuspected pulmonary embolism in patients with cancer. Soler S, Delgado C, Ballaz A, Cisneros E, Malý R, Babalis D, Monreal M; RIETE Investigators. **Thromb Res**. 2012 Apr;129 Suppl 1: S16-9.
104. Natural history of patients developing thrombocytopenia while receiving anticoagulant therapy for venous thromboembolism. Di Micco P, Fontanella A, Falvo N, Bonithon-Kopp C, Decousus H, Riera-Mestre A, Monreal M; RIETE Investigators. **Int Angiol**. 2012 Feb;31(1):92-5.
105. Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2). Knoebl P, Marco P, Baudo F, Collins P, Huth-Kühne A, Nemes L, Pellegrini F, Tengborn L, Lévesque H; EACH2 Registry Contributors. **J Thromb Haemost**. 2012 Apr;10(4):622-31
106. Clinical presentation and outcome of venous thromboembolism in COPD. Bertolotti L, Quenet S, Mismetti P, Hernández L, Martín-Villasclaras JJ, Tolosa C, Valdés M, Barrón M, Todolí JA, Monreal M; RIETE Investigators. **Eur Respir J**. 2012 Apr;39(4):862-8
107. Silent pulmonary embolism in patients with proximal deep vein thrombosis in the lower limbs. Tzoran I, Saharov G, Brenner B, Delsart D, Román P, Visoná A, Jiménez D, Monreal M; RIETE Investigators. **J Thromb Haemost**. 2012 Apr;10(4):564-71
108. Continuous infusion of rFVIII: a good choice for mild haemophilic patient undergoing major oncologic surgery and reconstructive plastic surgery. Barillari G, Pasca S. **Chirurgia**. 2012 Feb;25(1):84-5

109. Successful double bypass in a patient with severe hemophilia A: a case report. Barillari G, Pasca S, Erice F, Livi U. **J Thromb Thrombolysis**. 2012 Feb;33(2):193-6
110. Thrombocytopenia after infusion of an iodinated contrast medium: a case report. Barillari G, Pasca S. **J Clin Case Rep** 2012; 2:218.
111. Long-term therapy with low-molecular-weight heparin in cancer patients with venous thromboembolism. Marzoena PJ, Nieto JA, Guil M, García-Bragado F, Rabuñal R, Boccalon H, Trujillo-Santos J, Monreal M; RIETE Investigators. **Thromb Haemost**. 2012 Jan;107(1):37-43
112. Cancers in patients with hemophilia: a retrospective study from the Italian Association of Hemophilia Centers. Tagliaferri A, Di Perna C, Santoro C, Schinco P, Santoro R, Rossetti G, Coppola A, Morfini M, Franchini M; Italian Association of Hemophilia Centers. **J Thromb Haemost**. 2012 Jan;10(1):90-5.
113. Emergency reversal of anticoagulation: from theory to real use of prothrombin complex concentrates. A retrospective Italian experience. Barillari G, Pasca S, Barillari A, De Angelis V. **Blood Transfus**. 2012 Jan;10(1):87-94.
114. Effects of age on the risk of dying from pulmonary embolism or bleeding during treatment of deep vein thrombosis. Muñoz-Torrero JF, Bounameaux H, Pedrajas JM, Lorenzo A, Rubio S, Kearon C, Hernández L, Monreal M; Registro Informatizado de la Enfermedad TromboEmbólica (RIETE) Investigators. **J Vasc Surg**. 2011 Dec;54 (6 Suppl):26S-32S
115. Extended Compression Ultrasound Performed By Emergency Physicians: A Modified Compression Ultrasound Examination To Detect Superficial And Deep Lower Limb Thromboses In The Emergency. Barillari A, Barillari G, Pasca S. **J Med Ultrasound**, Nov 2011; 19: 103-8.
116. Vanishing bile duct syndrome in non-Hodgkin lymphoma: a case report. Foramiti S, Biondini E, Bigolin T, Pasca S, Rossi P. **Minerva Med**. 2011 Aug;102(4):345-9.
117. Prothrombin complex concentrate such as therapy and prophylaxis in factor X-deficient patient (Friuli variant). Barillari G, Pasca S, Gonano N, Daminato R. **Clin Appl Thromb Hemost**. 2011 Aug;17(4):332-6
118. Acute venous thromboembolism after non-major orthopaedic surgery or post-traumatic limb immobilisation. Findings from the RIETE registry. Bertolotti L, Righini M, Bounameaux H, López-Jiménez L, Tiraferri E, Visonà A, Monreal M; RIETE Investigators. **Thromb Haemost**. 2011 Apr;105(4):739-41
119. Thirty-day mortality rate in women with cancer and venous thromboembolism. Findings from the RIETE Registry. Trujillo-Santos J, Casas JM, Casado I, Samperiz AL, Quintavalla R, Sahuquillo JC, Monreal M; RIETE Investigators. **Thromb Res**. 2011 Feb;127 Suppl 3: S1-4
120. Clinical significance of a negative D-dimer level in patients with confirmed venous thromboembolism. Findings from the RIETE Registry. Soto MJ, Grau E, Gadelha T, Palareti G, Bounameaux H, Villalta J, Monreal M; RIETE Investigators. **J Thromb Haemost**. 2011 Feb;9(2):407-10.
121. Major bleeding as a predictor of mortality in patients with venous thromboembolism: findings from the RIETE Registry. Prandoni P, Trujillo-Santos J, Sanchez-Cantalejo E, Dalla Valle F, Piovella C, Pesavento R, Nieto Rodríguez JA, Monreal M; RIETE Group. **J Thromb Haemost**. 2010 Nov;8(11):2575-7.
122. Clinical characteristics and outcome of inpatients versus outpatients with venous thromboembolism: findings from the RIETE Registry. Maestre A, Sánchez R, Rosa V, Aujesky D, Lorenzo A, Barillari G, Monreal M; RIETE Investigators. **Eur J Intern Med**. 2010 Oct;21(5):377-82.
123. Simplification of the pulmonary embolism severity index for prognostication in patients with acute symptomatic pulmonary embolism. Jiménez D, Aujesky D, Moores L, Gómez V, Lobo JL, Uresandi F, Otero R, Monreal M, Muriel A, Yusen RD; RIETE Investigators. **Arch Intern Med**. 2010 Aug 9;170(15):1383-9.
124. Fatal bleeding in patients receiving anticoagulant therapy for venous thromboembolism: findings from the RIETE registry. Nieto JA, Solano R, Ruiz-Ribó MD, Ruiz-Gimenez N, Prandoni P, Kearon C, Monreal M; Riete Investigators. **J Thromb Haemost**. 2010 Jun;8(6):1216-22.
125. Retinal vein occlusion: evaluation of "classic" and "emerging" risk factors and treatment. Turello M, Pasca S, Daminato R, Dello Russo P, Giacomello R, Venturelli U, Barillari G. **J Thromb Thrombolysis**. 2010 Maggio;29(4):459-64

126. Bleeding complications associated with anticoagulant therapy in patients with cancer. Trujillo-Santos J, Nieto JA, Ruiz-Gamietea A, López-Jiménez L, García-Bragado F, Quintavalla R, Monreal M; RIETE Investigators. **Thromb Res**. 2010 Apr;125 Suppl 2:S58-61.
127. Venous thromboembolism during pregnancy, postpartum or during contraceptive use. Blanco-Molina A, Rota LL, Di Micco P, Brenner B, Trujillo-Santos J, Ruiz-Gamietea A, Monreal M; RIETE Investigators. **Thromb Haemost**. 2010 Feb;103(2):306-11.
128. Use of recombinant activated factor VII in severe post-partum haemorrhage: data from the Italian Registry: a multicentric observational retrospective study. Barillari G, Frigo MG, Casarotto M, Farnia A, Massè B, Wetzl R, Bianchin A, Rabi A, Malacarne P, Pasca S, Bigotto E; Italian rFVIIa-PPH Study Group. **Thromb Res**. 2009 Dec;124(6):e41-7
129. D-dimer levels and 15-day outcome in acute pulmonary embolism. Findings from the RIETE Registry. Lobo JL, Zorrilla V, Aizpuru F, Grau E, Jiménez D, Palareti G, Monreal M; RIETE Investigators. **J Thromb Haemost**. 2009 Nov;7(11):1795-801
130. Practical use of intermittent pneumatic compression as thromboprophylaxis in neurosurgery. Barillari G, Pasca S. **J Neurosurg Sci**. 2009 Jun;53(2):45-8. Review.
131. Coagulation and oxidative stress plasmatic levels in a type 2 diabetes population. Barillari G, Fabbro E, Pasca S, Bigotto E. **Blood Coagul Fibrinolysis**. 2009 Jun;20 (4): 290-6.

Abstracts:

1. High Risk of Acquired Rare Bleeding Disorders in Elderly Patients with Concomitant Haematological Diseases: A Single Center Experience. Pasca S, Agostini P, Novarese L, Boccagni P. Published on **Haemophilia**, 31(S1), Jan 2025
2. Real-World Use of Emicizumab in Surgery: A Systematic Review. Arcudi S, Pasca S, Peyvandi F. Published on **Haemophilia**, 31(S1), Jan 2025
3. Gender difference among blood donors: should laboratory ranges be changed? Pasca S, Secchi S, Postal L, Boccagni P. Accepted as poster SIMTI 2025
4. Improvement of transfusion activity using the electronic remote issue of packed red blood cells: the Trento experience. Menapace G, Carli C, Cleva L, Marzio G, Poda S, Altovino V, Pasca S, Secchi S, Boccagni P. (SIMTI 2024, accepted as poster). Published on **Blood Transfus** 22 (S1), May 2024
5. Specific serum biomarkers to assess the bone health in hemophilia A carriers: the CAR.BONE Study. Accepted (BIC-Conference 2023 - Palermo, accepted as Abstract). Pasca S, Giordano M, Faggian D, Basso D. Published on **Haemophilia** September 2023, 08.
6. Population pharmacokinetics of different clotting factor concentrates in fifty-six patients with severe hemophilia A; a single center experience (SISSET 2022 - Perugia, accepted as Poster). Pasca S, Zanon E. Published on **BTVB Journal**
7. Rationale and design of the "International Registry on the Symptomatic Hemophilia A/B Carriers". (ISTH 2021, accepted as Poster). Pasca S, Sidonio R Jr, Grandone E, Zanon E, Othman M; ISTH-SSC Women's Health issues on Thrombosis and Hemostasis. Published on **RPTH Journal**
8. High impact and severe outcomes of intracranial hemorrhage (ICH) in an Italian population of adult mild hemophilic patients: data from the EMO.REC Registry. Zanon E, Pasca S, Demartis F, Tagliaferri T, Santoro C, Cantori I, Molinari AC, Biasoli C, Coppola A, Castanan G, Linari S, Luciani M, Sottilotto G, Ricca I, Pollio B, Borchellini A, Tosetto A, Santagostino E. (ISTH 2021, accepted as Live ePoster). Published on **RPTH Journal**
9. Population Pharmacokinetics of rFXIII (catridecacog) and clinical outcomes of prophylaxis in an Italian population of patients with Factor XIII deficiency. Zanon E, Pasca S, Sottilotto G, Molinari AC, Banov L, Ferretti A, Di Gregorio P, Pollio B, Siboni SM, Palla R, Peyvandi F, Pizzuti M, Notarangelo LD, Simioni P, Cojutti P, Biasoli C, Pea F. (ISTH 2021, accepted as Poster). Published on **RPTH Journal**
10. Cost-effectiveness of rFVIII single chain in an Italian population of hemophilia A patients: the Veneto experience. Zanon E, Pasca S, Radossi P, Bonetti E, Giuffrida AC, Tosetto A. (ISTH 2021, accepted as Poster). Published on **RPTH Journal**.
11. Catridecacog in the treatment of an Italian population of patients with FXIII deficiency: from pharmacokinetics to clinical outcomes (The Italian rFXIII study) Zanon E, Pasca S, Sottilotto G, Molinari AC, Banov L, Ferretti A, Di Gregorio P, Pollio B, Siboni SM, Palla R, Peyvandi F, Pizzuti M, Notarangelo LD, Simioni P, Cojutti P, Biasoli C, Pea F. (BIC-Conference 2021, accepted as Poster). Published on **Haematologica Journal**.

12. An Italian Survey on the real-world use of rFXIII (catridecacog) in patients with factor XIII deficiency. Zanon E, Pasca S, Sottilotta G, Molinari AC, Banov L, Ferretti A, Di Gregorio P, Pollio B, Siboni SM, Palla R, Spiezia L, Pizzuti M, Notarangelo LD, Simioni P. (SIST 2020, accepted as Oral Presentation). Published on **Blood Transfus** Journal.
13. Is intracranial haemorrhage in haemophilia patients still a present risk in the third millennium? The final results of the EMO.REC Registry: a 10-year Italian study on intracranial haemorrhage in haemophilia patients. Zanon E, Pasca S, Demartis F, Tagliaferri T, Santoro C, Cantori I, Molinari AC, Biasoli C, Coppola A, Castanan G, Linari S, Luciani M, Sottilotta G, Ricca I, Pollio B, Borchellini A, Santagostino E. (SIST 2020, accepted as Oral presentation). Published on **Blood Transfus** Journal.
14. Real World Experience on use of susoctocog-alfa (rpFVIII) in the treatment of a population of Italian elderly patients with acquired haemophilia A. Zanon E, Pasca S, Borchellini A, Lodigiani C, Molinari AC, Moscatelli P, Ambaglio C, Preti PS, Simioni P (WFH 2020, accepted as Poster). Published on **Blood Transfus** Journal.
15. Clinical, psychological and physical aspects of hemophilia: face to face between North and South Italy. Pasca S, Villa MR, Zanon E, Rocino A. (AICE 2020, Milan. Accepted as poster). Published on **Blood Transfus** Journal.
16. Incidence, management and outcomes of intracranial haemorrhage in haemophilia patients: a 10-year Italian study - the final results of the EMO.REC Registry. Zanon E, Pasca S, Demartis F, Tagliaferri T, Santoro C, Cantori I, Molinari AC, Biasoli C, Coppola A, Castanan G, Linari S, Luciani M, Sottilotta G, Ricca I, Pollio B, Borchellini A, Santagostino E. (AICE 2020 Milan, accepted as Oral presentation). Published in **Blood Transfus** Journal.
17. Comparison between three different bleeding scores and the Thrombin Generation Assay (TGA) to assess the haemorrhagic phenotype in patients with different degrees of FVII deficiency. Milan M, Pasca S, Santoro C, Ambaglio C, Napolitano M, Natali L, Nannizzi S, Mori F, Zanon E (AICE 2020 Milan, accepted as Oral presentation). Published on **Blood Transfus** Journal.
18. Registry and International Efforts Around Hemophilia Carriers. Pasca S, Sidonio R. Jr. (ISTH meeting- SSC on Women's Health Issues 2020, Oral presentation). Published in **RPTH** Journal.
19. Real World Experience on use of susoctocog-alfa (rpFVIII) in the treatment of a population of Italian elderly patients with acquired haemophilia A. Zanon E, Pasca S, Borchellini A, Lodigiani C, Molinari AC, Moscatelli P, Ambaglio C, Preti PS, Simioni P (ISTH 2020, accepted as Poster). Published on **RPTH** Journal.
20. An Italian Survey on the real-world use of rFXIII (catridecacog) in patients with Factor XIII deficiency. Zanon E, Pasca S, Sottilotta G, Molinari AC, Banov L, Ferretti A, Di Gregorio P, Pollio B, Siboni SM, Palla R, Spiezia L, Pizzuti M, Notarangelo LD, Simioni P. (ISTH 2020, accepted as Poster). Published on **RPTH** Journal.
21. Is intracranial haemorrhage in haemophilia patients still a present risk in the third millennium? The final results of the EMO.REC Registry: a 10-year Italian study on intracranial haemorrhage in haemophilia patients. Zanon E, Pasca S, Demartis F, Tagliaferri T, Santoro C, Cantori I, Molinari AC, Biasoli C, Coppola A, Castanan G, Linari S, Luciani M, Sottilotta G, Ricca I, Pollio B, Borchellini A, Santagostino E. (ISTH 2020, accepted as Poster). Published on **RPTH** Journal.
22. The real-life use of rFXIII (catridecacog) in patients with severe Factor XIII deficiency: an Italian survey. Pasca S, Sottilotta G, Molinari AC, Banov L, Ferretti A, Di Gregorio P, Pollio B, Siboni SM, Palla R, Spiezia L, Pizzuti M, Notarangelo LD, Ezio Zanon E., (WFH 2020, accepted as Free Oral Presentation). Published on **Haemophilia** Journal.
23. The pink color of haemophilia: two emblematic cases of severe complications in haemophilia A carriers. Pasca S, Fasolato S, Berizzi A, Zanon E. (WFH 2020, accepted as Poster)
24. Intracranial hemorrhage an open issue: a 10-year Italian study on intracranial haemorrhage in haemophilia patients, the final results of the EMO.REC Registry. Zanon E, Pasca S, Demartis F, Tagliaferri T, Santoro C, Cantori I, Molinari AC, Biasoli C, Coppola A, Castanan G, Linari S, Luciani M, Sottilotta G, Ricca I, Pollio B, Borchellini A, Santagostino E. (WFH 2020, accepted as Oral Presentation). Published on **Haemophilia** Journal.
25. The role of nurses in the management of treatment, in education and in improving the quality of life of families living with haemophilia. Rossetto F, Radossi P, Tosetto A, Zanon E, Loteni ML, Pasca S (WFH 2020, accepted as Poster)
26. The successful use of susoctocog-alfa (rpFVIII) in the treatment of nine elderly patients presenting acquired haemophilia A: a multicenter case series. Zanon E, Pasca S, Borchellini A, Lodigiani C, Molinari AC, Moscatelli P, Ambaglio C, Preti PS, Simioni P (WFH 2020, accepted as Free Oral Presentation). Published on **Haemophilia** Journal.

27. Immune tolerance induction rescue (ITI-R) with human-cl rhFVIII in haemophilia A patients and high-titre inhibitors. Zanon E, Pasca S, Marino R, Ricca I, Pollio B (10th BIC and 3rd Inhibitors in Hemophilia International Conference), Settembre 2019. Published on **Haematologica** Journal.
28. Final data from the Italian Registry on intracranial haemorrhage in haemophilia patients: EMO.REC Registry (2009-2018). Zanon E, Pasca S, Santoro C, Linari S, Pollio B, Tagliaferri A, Cantori I, Biasoli C, Molinari CA, Santagostino E. (ISTH 2019, Melbourne), Luglio 2019. Published on **RPTH** Journal.
29. Results from the Immune Tolerance Induction (ITI) with moroctocog-alpha in a population of haemophilia A patients and high-titre inhibitors: the REF.IT Registry. Zanon E, Pasca S, Coppola A, Castaman G, Linari S, Pollio B, Santoro C, Schinco P, Milano M, Santagostino E, Rocino A, Marino R, Siragusa S, Aru B, Tagliaferri A. (ISTH 2019, Melbourne), Luglio 2019. Published on **RPTH** Journal.
30. High risk of intracranial haemorrhage in adult mild haemophiliac patients: data from the EMO.REC Registry. Zanon E, Pasca S, Santoro C, Linari S, Pollio B, Tagliaferri A, Cantori I, Biasoli C, Molinari CA, Santagostino E. (ISTH 2019, Melbourne), Luglio 2019. Published on **RPTH** Journal.
31. Simoctocog-alfa (rhFVIII): an interesting option for the Immune Tolerance Induction Rescue (ITI-R) in the hemophilia A patients with high-titer inhibitors. Zanon E, Pasca S, Marino R, Ricca I, Pollio B. (ISTH 2019, Melbourne), Luglio 2019. Published on **RPTH** Journal.
32. Three successful cases of AHA patients presenting severe cardiovascular diseases treated with susoctocog-alfa (rpFVIII): a single centre experience. Zanon E, Pasca S, Campello E, Spiezia L, Simioni P. (ISTH 2019, Melbourne), Luglio 2019. Published on **RPTH** Journal.
33. Successful Immune Tolerance Induction Rescue (ITI-R) with simoctocog alfa (rhFVIII) in hemophilia A patients and high-titer inhibitors: three case reports. Zanon E, Pasca S, Marino R, Ricca I, Pollio B. (EAHAD, Praga), Febbraio 2019. Published on **Haemophilia** Journal.
34. Fostering drug storage, preparation and treatment modalities improves adherence to treatment with turoctocog-alfa in patients with haemophilia A: Results from a short-term follow-up. Napolitano M, Marino R, Baldacci E, Coluccia A, Cultrera D, Luciani M, Pasca S, Pieri L, Ricca I, Barillari G, Ettorre C, Linari S, Valeri F, Siragusa S, Rocino A. (EAHAD, Praga), Febbraio 2019. Published on **Haemophilia** Journal.
35. Two cases of successful Immune Tolerance Induction Rescue (ITI-R) with simoctocog alfa (rhFVIII) in hemophilia A patients and high-titer inhibitors. Zanon E, Pasca S, Marino R, Molinari AC. (ASH, San Diego-USA), Dicembre 2018. Published on **Blood** Journal.
36. Adult patients with mild haemophilia: an undervalued population, but at high risk for intracranial haemorrhage (data from the EMO.REC Registry). Zanon E, Pasca S, Tagliaferri A, Cantori I, Molinari CA, Biasoli C, Coppola A, Castaman G, Linari S, Luciani M, Pollio B, Santagostino E. (XXV SISET, Firenze) Novembre 2018. Published on **Blood Transfus** Journal
37. Retrospective evaluation of phenotype and management of Dysfibrinogenemia and -Hypofibrinogenemia in a cohort of Italian patients. Santoro C, Baldacci E, Ferretti A, Santoro RC, Pasca S, Borchellini A, Castaman G, Peyvandi F, Mazzucconi MG. (XXV SISET, Firenze) Novembre 2018. Published on **Blood Transfus** Journal
38. Retrospective evaluation of phenotype and management of A-Hypo-Fibrinogenemia in a cohort of Italian patients. Santoro C, Baldacci E, Ferretti A, Santoro RC, Pasca S, Nichele I, Poz A, Radossi P, Castaman G, Peyvandi F, Mazzucconi MC. (XXV SISET, Firenze) Novembre 2018. Published on **Blood Transfus** Journal
39. Coagulation monitoring of severe haemophilia A patient undergoing emicizumab therapy. Bulato C, Zanon E, Campello E, Pasca S, Saggiorato G, Spiezia L, Radu CM, Simioni P. (XXV SISET, Firenze) Novembre 2018. Published on **Blood Transfus** Journal
40. Three cases of successful Immune Tolerance Induction Rescue (ITI-R) with three different recombinant FVIII (rFVIII) in hemophilia A patients and high-titer inhibitors. Pasca S, Zanon E (XXV SISET, Firenze) Novembre 2018. Published on **Blood Transfus** Journal 8.
41. The perception of pain in children with haemophilia, and its impact on their lives: a case-control study. Pasca S, Loteni ML, Zanon E. (WFH 2018 World Congress, Glasgow) Maggio 2018
42. Retrospective evaluation of phenotype and management of A-Hypo-Fibrinogenemia in a cohort of Italian patients. Santoro C, Massaro F, Baldacci E, Ferretti A, Santoro RC, Pasca S, Peyvandi F, Castaman G, Mazzucconi MC. (WFH 2018 World Congress, Glasgow) Maggio 2018. Published on **Haemophilia** Journal.
43. Optimizing the treatment: the precision medicine using *MyPKfit* in a population of patients with moderate or severe hemophilia A. Zanon E, Milano M, Sarolo L, Pasca S. (WFH 2018 World Congress, Glasgow) Maggio 2018. Published on **Haemophilia** Journal.

44. Immune Tolerance Induction with moroctocog-alpha (Refacto/Refcto AF) in a population of haemophilia A patients and high-titre inhibitors: data from REF.IT Registry. Zanon E, Pasca S, Coppola A, Castaman G, Linari S, Pollio B, Santoro C, Schinco P, Milano M, Santagostino E, Rocino A, Marino R, Siragusa S, Aru B, Tagliaferri A. (WFH 2018 World Congresso, Glasgow) Maggio 2018 Published on **Haemophilia** Journal.
45. Cost-effectiveness of efmoctocog-alpha in the treatment of severe haemophilia A patients: a single Centre experience. Zanon E, Milan M, Pasca S. (WFH 2018 World Congresso, Glasgow) Maggio 2018. Published on **Haemophilia** Journal.
46. High risk of intracranial haemorrhage in adult mild haemophilic patients: data from the EMO.REC Registry. Zanon E, Pasca S, Milan M, Linari S, Pollio B, Tagliaferri A, Cantori I, Biasoli C, Molinari CA, Santagostino E. (WFH 2018 World Congresso, Glasgow) Maggio 2018
47. The sudden appearance of inhibitors in a severe haemophilia B previously treated patient after the switch to albutrepenonacog alpha. Pasca S, Milano M, Zanon E. (2nd Inhibitor Conference, Milano) Marzo 2018. Published on **Haematologica** Journal.
48. Results from Italian Registry on activated prothrombin complex concentrate in acquired hemophilia A: the FAIR study. Zanon E, Milano M., Gamba G, Giuffrida G, Falanga.A, Federici AB; Cantori I, Siragusa S, Mazzucconi MG, Piseddu G, Rocino A, Santoro RC, Pasca S, Lodigiani C. (ISTH XXVI Congresso Abstracts), Luglio 2017. Published on **RPTH** Journal.
49. Efficacy and safety of combined use of aPCC and antifibrinolytics in acquired hemophilia A: results from the FAIR Registry. Zanon E, Pasca S, Gamba G, Giuffrida G, Falanga.A, Federici AB; Cantori I, Siragusa S, Mazzucconi MG, Piseddu G, Rocino A, Santoro RC, Lodigiani C. ISTH XXVI Congresso Abstracts), Luglio 2017. Published on **RPTH** Journal.
50. Low dose of aPCC as short-term prophylaxis after the end of initial treatment of acquired hemophilia A to reduce bleeding recurrences: data from the FAIR Registry (Zanon E, Pasca S, Gamba G, Giuffrida G, Falanga.A, Federici AB; Cantori I, Siragusa S, Mazzucconi MG, Piseddu G, Rocino A, Santoro RC, Lodigiani C. (ISTH XXVI Congresso Abstracts), Luglio 2017. Published on **RPTH** Journal.
51. Tailored prophylaxis in children with hemophilia A: a new approach for the future. Pasca S, Milano M, Cogo P, Sarolo L, Zanon E. (ISTH XXVI Congresso Abstracts), Luglio 2017. Published on **RPTH** Journal.
52. Retrospective evaluation of phenotype and management of a-hypo-dys-fibrinogenemia in a cohort of Italian patients. Santoro C, Massaro F, Baldacci E, Ferrara G, Santoro RC, Pasca S, Castaman G, Peyvandi F, Mazzucconi MG (X EAHAD Congresso), Feb 2017. Published on **Haemophilia** Journal.
53. Switch from vitamin K antagonists (VKAs) to Direct Oral Anticoagulants (DOACs): a practical approach. Pasca S, Venturelli U, Bertone A, Barillari G. . (ISTH XXV Congresso Abstracts), Giugno 2015. Published on **JTH** Journal.
54. Efficacy of FVIII in the treatment of patients with acquired haemophilia A and vascular diseases. Pasca S, Battello C, Barillari G. . (ISTH XXV Congresso Abstracts), Giugno 2015. Published on **JTH** Journal.
55. Rivaroxaban in patients with VTE and cancer: a single center experience. Pasca S, Venturelli U, Bertone A, Barillari G. . (ISTH XXV Congresso Abstracts), Giugno 2015. Published on **JTH** Journal.
56. Natural history and antithrombotic treatment of incidentally detected splanchnic vein thrombosis: findings from the ISTH registry. Riva N, Ageno W, Schulman S, Beyer-Westendorf J, Bang SM, Pasca S, Poli D, Verhamme P, Alatri A, Colaizzo D, Rancan E, Rezende SM, Piana. Published on **JTH** Journal.
57. A, Bazzan M, De Sancho MT, Ciantar E, Elli E, Zawilska K, Dentali F and IRSVT study investigators. (ISTH XXV Congresso Abstracts), Giugno 2015. Published on **JTH** Journal.
58. Cancers in patients with von Willebrand disease: a survey from the Italian association of hemophilia centres. Tagliaferri A, Castaman G, Di Perna C, Santoro C, Siboni SM, Zanon E, Linari S, Gresele P, Pasca S, Coppola A, Santoro R, Paola R, Napolitano M and Franchini M. (ISTH XXV Congresso Abstracts), Giugno 2015. Published on **JTH** Journal.
59. The role of rFVIIa in 14 patients with mild congenital FVII deficiency in case of spontaneous haemorrhage or surgery: a single centre case series. Pasca S, Turello M, Barillari G. (VI EAHAD Congresso), Feb 2013. Published on **Haemophilia** Journal.
60. Recurrent thrombotic events after discontinuation of vitamin k antagonist treatment for splanchnic vein thrombosis: a multicenter retrospective cohort study. Riva N, Ageno W, Poli D, Testa S, Pedrini S, Marigo L, Sivera P, Pasca S, Malcangi G, Giobatta C, Falco P, Ruocco L, Paparo C, Bucherini E, Suriano L, Ria L, Tosetto A and On behalf of Italian Federation of Anticoagulation Clinics (FCSA)
61. Thromboprophylaxis with two different dosages of LWMH (calcic nadroparin) in pregnant women with thrombophilia: a single center experience Barillari G, Venturelli U, Turello M, Pasca S (SSC-ISTH, Liverpool 2012)
62. Profilassi del TEV con fondaparinux in medicina interna. Silvestri F, Labombarda A, Barbi A, Burri R, Desideri M, Guidi P, Rogato A, Zaramella M, Pasca S, Barillari G. Italian J Med, 2011. (XVI Congresso FADOI).

63. Malignancies in patients with haemophilia. Tagliaferri A, Di Perna C, Santoro C, Schinco P, Santoro R, Rossetti G, Coppola A, Morfini M, Castaman G, Scaraggi FA, Pasca S, Macchi S, Valdré L, Zanon E, Serino M, Napolitano M, Cantori I, Giuffrida A, Delios G, Radossi P, Franchini M. (ISTH XXIII Congresso Abstracts), Luglio 2011. Published on **JTH** Journal.
64. Long Term Follow Up of Allogeneic Peripheral Blood Stem Cell Donors. A Single Institution Experience on 190 Donors. Rinaldi C, Savignano C, Pasca S, Sperotto A, Patriaca F, Fanin R, De Angelis V. (AABB Annual Convegno Abstracts), Oct 2011.
65. Use of Recombinant Activated Factor VII in Severe Post-Partum Haemorrhage: Data from the Italian Registry. A Multicentric Observational Retrospective Study. Barillari G., Frigo MG., Casarotto M., Farnia A., Massè B., Wetzl R., Bianchin A., Rabi A., Malcarne P., Pasca S., Bigotto E. and Dentali F. (ASH Annual Convegno Abstracts), Nov 2009. Published on **Blood** Journal.

Other publications:

1. "EMOFILIA: Sostantivo femminile (storie ed aneddoti di madri e sorelle portatrici di emofilia)" - Pasca S, Bellandi G. 2023
2. Prevenzione del tromboembolismo venoso in chirurgia ortopedica e traumatologica. Barillari G, Pasca S. 2013
3. Pratica guida alla profilassi della malattia tromboembolica venosa in ambito chirurgico. Barillari G, Pasca S. 2012

Projects

"Registry and International Efforts Around Hemophilia Carriers" virtual presentation SSC-ISTH Women's Health Issues in T&H (29 Jun 2020), ora su piattaforma RedCap-ISTH con il titolo "International Registry on Hemophilia A/B Carriers" (Project Leader assieme a Robert Sidonio jr).

Formazione Continua(Congressi, Convegni, Corsi)

Relatore:

1. Convegno "Dialoghi sull'emofilia A". Villasi (VR), 29 Settembre 2024
2. Convegno "Every Three Months Talks #14 – medical topics worth deeping. Coagulazione". Trento, 22 Maggio 2024
3. Convegno "Emofilia e MEC in Trentino: cambio di paradigma", Trento 17 Aprile 2024
4. Commissioni AICE "Associazioni", Catanzaro 12-13 Aprile 2024
5. Convegno: "Nuove sfide nel trattamento globale del bambino e adulto con emofilia", Padova 30 Settembre-01 Ottobre 2022
6. Commissioni AICE "Farmacocinetica e MEC-donna", Roma 11-12 Aprile 2022
7. Convegno: "Nuove sfide nel trattamento globale del bambino e adulto con emofilia", Padova 07-08 Ottobre 2021
8. Congresso "ISTH2020 – Virtual Congress", 29 Giugno 2020
9. Convegno "Hembracelife: continuiamo a costruire insieme il futuro dell'emofilia", Torino 20-21 Febbraio 2020
10. Expert Panel "Serenissima Experience", Vicenza 23 Gennaio 2020
11. Corso: "What you do today matters for the future. Connecting haemophilia care", Venezia 17-18 Dicembre 2019
12. Corso: "Butterfly 2.0: il counseling terapeutico nel paziente emofilico", Padova 03 Dicembre 2019
13. Corso: "Ecografia articolare in emofilia nella pratica clinica", Padova 23 Novembre 2019
14. Convegno: "L'emofilia nell'età pediatrica nel Triveneto", Verona 22 Novembre 2019
15. Convegno "Te.O.R.Em.A 2.0", Milano 15 Novembre 2019
16. Convegno: "PROPER: Profilassi personalizzata in emofilia". Roma, 28 Ottobre 2019
17. Convegno: "Nuove sfide nel trattamento globale del bambino e adulto con emofilia", Padova 18-19 Ottobre 2019
18. Convegno: "riPensiamo l'Emofilia B, Roma 28 Maggio 2019
19. Convegno: "eSPORTiamo l'emofilia", Milano 04 Maggio 2019

20. Convegno: "Emotional Experience. I legami forti durano più a lungo", Roma 28 Febbraio – 01 Marzo 2019
21. Corso: Il counseling terapeutico nel paziente emofilico (Progetto Butterfly)", Padova 26 Febbraio 2019
22. Corso: "Progetto Port-eight", Roma 20 Ottobre 2018
23. Corso: "Ho fatto 13 (FXIII)". Milano 16-17 Ottobre 2018
24. Convegno: "Be more Alert", Mantova 13 Ottobre 2018
25. Tavola rotonda: MyPKFit. Milano 02 Ottobre 2018 (Trainer Fase 2)
26. Convegno: "TE.O.RE.MA, Terapia, Opportunità e Risposte in Emofilia A. Milano 29 Settembre 2018
27. Convegno: "Nuove sfide nel trattamento globale del bambino e adulto con emofilia", Padova 21-22 Settembre 2018
28. Tavola rotonda: MyPKFit. Milano 20 Settembre 2018 (Trainer Fase 1)
29. Convegno: "Haemo in Tour2018". Roma 06-07 Luglio 2018
30. Corso di formazione "La profilassi personalizzata in emofilia", Milano 11 giugno 2018
31. Convegno: "L'alleanza efficace nella gestione del paziente emofilico", Padova 18 aprile 2018
32. Convegno "AHA Today: analisi e discussione della gestione del paziente con emofilia acquisita", Padova 13 Ottobre 2017
33. Convegno SIFO-Veneto "Malattie rare: sostenibilità dell'accesso alle cure e dei bisogni assistenziali in regione Veneto. Nuovi orientamenti nel trattamento dell'emofilia", Padova 20 Giugno 2017
34. Convegno: "All in: opinioni a confronto in emofilia e malattie rare della coagulazione", Milano 15-16 Giugno 2017
35. 2° Corso di formazione "Nuove strategie terapeutiche nel trattamento del bambino e adulto con emofilia: tradizionale e nuovi farmaci a confronto", Padova 09-10 Giugno 2017
36. Convegno "Importanza Clinica della Profilassi Personalizzata per il trattamento dell'emofilia", Padova 14 Ottobre 2016
37. Congresso "X-Up-Date in Gastroenterologia", Udine, 07-08 Novembre 2014
38. Regional Congresso "ARCA sez. Veneto", Mestre (VE), 04 Ottobre 2014
39. Convegno "Controversie nella gestione del tromboembolismo: incontro Triveneto" – Padova, 08 Giugno 2013

Partecipante:

1. XVIII Annual Congress of European Association for Haemophilia and Allied Disorders (EAHAD) – Milano 04-07 February 2025
2. Convegno: "Nuove sfide nel trattamento globale del bambino e adulto con emofilia", Padova 25-26 Ottobre 2024
3. Convegno Associazione Italiana Centri Emofilia (AICE), Roma 10-12 Ottobre 2024
4. XXXII Congress of International Society Thrombosis Haemostasis (ISTH) – Bangkok 22-26 June 2024
5. Convegno "Hembrace: the Moment". Bologna, 10-11 Maggio 2024
6. Convegno Associazione Italiana Centri Emofilia (AICE), Salerno, 13-15 Ottobre 2022
7. XXX Congress of International Society Thrombosis Haemostasis (ISTH) – Virtual, London 09-13 July 2022
8. Corso "Big data e intelligenza artificiale in medicina di laboratorio" online, 18 Maggio 2022
9. Corso di Formazione "Meetings di aferesi terapeutica 2022". Virtual, da 20/01 a 07/04/2022
10. Corso "Il monitoraggio terapeutico del farmaco; il ruolo del laboratorio nell'ambito della terapia centrata sul paziente" online, 06 Aprile 2022
11. Convegno Associazione Italiana Centri Emofilia (AICE), Roma, 14-16 Ottobre 2021
12. 11th BIC and 3rd Inhibitors in Hemophilia International Conference, Venezia 17-21 Settembre 2021
13. XXIX Congress of International Society Thrombosis Haemostasis (ISTH) – Virtual, Philadelphia 17-21 July 2021
14. Convegno Associazione Italiana Centri Emofilia (AICE), Milano, 09-11 Ottobre 2020
15. Corso "Haemofeeling", Parma 25 Settembre 2020
16. XXVIII Congress of International Society Thrombosis Haemostasis (ISTH) – Virtual, Milano 12-14 Jul 2020
17. Convegno Associazione Italiana Centri Emofilia (AICE), Rimini, 07-09 Novembre 2019
18. Convegno: "PROPER: Profilassi personalizzata in emofilia". Roma, 28 Ottobre 2019
19. Corso: "Joint in class. Il danno articolare: prevenire insieme in tempo", Roma 25-26 Ottobre 2019

20. 10th BIC and 3rd Inhibitors in Hemophilia International Conference, Genova 06-08 Settembre 2019
21. XXVII Congresso of International Society Thrombosis Haemostasis (ISTH) – Melbourne, 06-10 Luglio 2019
22. Corso: “La gestione multidisciplinare del paziente emofilico”, Roma, 22-23 Gennaio 2019
23. Convegno Associazione Italiana Centri Emofilia (AICE), Milano, 15-17 Novembre 2018
24. XXV Congresso “Italian Society for Thrombosis and Haemostasis” (SISSET), Firenze 07-10 Novembre 2018
25. Congresso “WFH 2018 World Congresso”, Glasgow 20-24 Maggio 2018
26. Corso “Haemodol, emofilia e dolore: call to action”, Bologna 06 Aprile 2018
27. Convegno “Hemopower Life”, Bologna 27 Gennaio 2018
28. Convegno Triennale AICE. Napoli, 11-12 Novembre 2017
29. Corso Residenziale “SISSET Training Center – Corso Trombosi”, Piacenza 6-10 Novembre 2017
30. Convegno “Focus on eight -Scegliere un FVIII oggi”, Desenzano del Garda (BS), 27-28 Ottobre 2017
31. Convegno “Bleeding emergency in acquired haemophilia A lead to early recognition and treatment”, Padova 20 Ottobre 2017
32. Convegno “InhibiTour 2.0: La profilassi si fa strada nel paziente con inibitore”, Vimercate (MB), 29-30 Settembre 2017
33. Investigators Convegno “STASEY M039129”, Barcellona 21 Settembre 2017
34. Investigators Convegno “VON-rvW”, Roma 13-14 Settembre 2017
35. XXVI Congresso of International Society Thrombosis Haemostasis (ISTH) – Berlino, 08-12 Luglio 2017
36. Convegno “La malattia di vonWillebrand: un approccio orientato al paziente dalla diagnosi al trattamento”, Firenze 30 Giugno 2017
37. Convegno: “reSET Acquired Haemophilia A: an integrated patient journey towards innovation”, Roma 22-23 Maggio 2017
38. Convegno: “L’innovazione in emofilia: 50 anni di progresso”, Otranto (LE) 12-14 Maggio 2017
39. Convegno: “S.T.O.R.I.E- Semplicità della Terapia e Ottimizzazione delle Risorse - nuovi traguardi In Emofilia”, Bologna 09 Marzo 2017
40. XXIV Congresso “Italian Society for Thrombosis and Haemostasis” (SISSET), Abano Terme (PD) 09-12 Novembre 2016
41. Convegno “Italian Haemophilia Centers Association” (AICE), Bologna 26-28 Ottobre 2016
42. Convegno “ Nuove coordinate per l'emofilia B”, Milano 07 Ottobre 2016
43. Convegno “InhibiTour 2.0: La profilassi si fa strada nel paziente con inibitore”, Roma, 17-19 Settembre 2016
44. Convegno Il bambino con l'emofilia” Padova 13-14 Maggio 2016
45. Convegno “RETHINK HAEMOPHILIA”, Padova 18-19 Marzo 2016
46. Convegno “ LMC: scenari e potenzialità dei TKI di II generazione”, Udine, 23 Ottobre 2015
47. Convegno “Italian Haemophilia Centers Association” (AICE), Napoli, 30 Settembre -02 Ottobre 2015
48. Convegno “Managing haemophilia for life”, Prague, 24-26 Settembre 2015
49. Corso pratico “Uso dell'ecografia nell'artropatia emofilica”, Padova, 21 Settembre 2015
50. Convegno “InhibiTour: il trattamento dell'inibitore si fa strada in emofilia”, Bergamo, 17-19 Settembre 2015
51. Convegno “2 Go Together”, Roma 15-16 Maggio 2015
52. Convegno “I...(non più nuovi) anticoagulanti orali in cardiologia”, Varna (BZ), 10-11 Aprile 2015
53. Convegno “Rate or Rhythm 2014, the odd question”, Bosco (PG), 26-28 Novembre 2014
54. Convegno “Managing haemophilia for life”, Barcellona, 25-27 Settembre 2014
55. Convegno “The laboratory between old and new oral anticoagulants: the state of the art”, Codroipo (UD), 21 Maggio 2014
56. Convegno “Haemocases – orientarsi nella pratica clinica”, Roma 30-31 Gennaio 2014
57. Investigators Convegno “RIETE”, Milano 30 Novembre 2013
58. Convegno “Managing haemophilia for life”, Potsdam, 26-28 Settembre 2013
59. International haemophilia Convegno “Haemophilia A and inhibitors: advances in prevention and ITI treatment optimization” – Barcellona, 21 Settembre 2013
60. XXIV Congresso of International Society Thrombosis Haemostasis (ISTH) – Amsterdam, 29 Giugno 04 Luglio 2013
61. Convegno “Giornate friulane sulle malattie emorragiche e trombotiche – 3ª edizione” – Udine, 07 Giugno 2013

62. Convegno "Haemocases – orientarsi nella pratica clinica", Roma 24-25 Gennaio 2013
63. Convegno "Italian Haemophilia Centers Association" (AICE), Firenze 05-07 Novembre 2012
64. XXIII National Congresso FCSA, Parma 26 Ottobre 2012
65. Convegno "Giornate friulane sulle malattie emorragiche e trombotiche – 2^a edizione" – Udine, 25 Maggio 2012
66. Congresso EAHAD "European Association Hemophilia and Allied Disorders", Roma 22-24 Febbraio 2012
67. Investigator Convegno "Pathfinder 2&3", Amsterdam 17-19 Gennaio 2012
68. Convegno "Haemocases", Roma 12-13 Gennaio 2012
69. Investigator Convegno "Warfasa", Bologna 24 Novembre 2011
70. XIII Congresso "Italian Haemophilia Centers Association" (AICE), Firenze 04-06 Novembre 2011
71. XXII National Congresso FCSA (Federation Centres for the diagnosis of thrombosis and monitoring of antithrombotic therapies), Parma 03 Novembre 2011
72. Convegno "Hematology Conference – Achieving progress in a changing world", Budapest 13-15 Ottobre 2011
73. II Convegno FCSA (Federation Centres for the diagnosis of thrombosis and monitoring of antithrombotic therapies), Parma 24 Giugno 2011
74. Convegno "Hemostatic therapy in the haemorrhagic emergencies", Udine 04 Giugno 2011
75. Convegno "Orthopedic surgery in haemophilic patients with inhibitors" Milano 13 Maggio 2011
76. Investigators Convegno "Hokusai-VTE", Athens 25-26 Marzo 2011
77. Investigators Convegno "Amplify and Amplify-Ext", Rome 26 Febbraio 2011
78. Congresso EAHAD "European Association Hemophilia and Allied Disorders", Ginevra 02-04 Febbraio 2011
79. Convegno "Managing haemophilia for life", Rome 27-28 Novembre 2010
80. Convegno "Management of the hematological patient between hospital and territory", Mortegliano (UD) 20 Novembre 2010
81. Convegno "Focus on: thromboembolism in oncology", Palmanova (UD) 12 Novembre 2010
82. Congresso "Italian Society for Thrombosis and Haemostasis" (SISSET), Bologna 28-31 Ottobre 2010
83. Convegno "Italian Haemophilia Centers Association" (AICE), Milano 20-21 Ottobre 2010
84. Congresso "World Federation of Haemophilia – WFH", Buenos Aires 10-14 Luglio 2010
85. Convegno "Haemophilic Artropaty", Firenze, 24 Giugno 2010
86. Convegno "The thromboembolic disease", Pordenone 15 Maggio 2010
87. Convegno "Management of thromboembolic disease", Udine 08 Maggio 2010
88. Convegno "Prophylaxis and therapy of venous thromboembolism", Udine 13 Novembre 2009
89. Convegno "Italian Haemophilia Centers Association" (AICE), Milano 14-15 Ottobre 2009
90. Congresso "Italian Society of Chemotherapy", Udine 11-14 Ottobre 2009
91. Convegno "Focus on: Resist, g-ITI, Prowill and Sippet Studies" Monsumanno Terme, 04 Aprile 2009
92. Convegno "Italian Haemophilia Centers Association" (AICE), Milano 18-19 Marzo 2009

*2020/2021 partecipato a diversi corsi/convegni virtuali cin qualità sia di relatore che di semplice partecipante che non sono stati qui indicati

Attività di Ricerca Clinica (Sub-investigator o Study Coordinator)

- **Studio ATLAS OLE:** An Open-label, Long-term Safety and Efficacy Study of Fitusiran in Patients with Hemophilia A or B, with or without Inhibitory Antibodies to Factor VIII or IX

- **Studio POWER:** Studio Multicentrico non-interventistico, mirato a valutare l'attività fisica, l'incidenza dei sanguinamenti, la qualità della vita nei pazienti con emofilia A senza inibitori in un regime di trattamento da pratica clinica (ML40983)
- **Studio ATLAS A/B:** Studio di fase 3 per valutare l'efficacia e la sicurezza di fitusiran in pazienti affetti da emofilia A o B, senza anticorpi inibitori del fattore VIII o IX
- **Studio ATLAS-INH:** Studio di fase 3 per valutare l'efficacia e la sicurezza di fitusiran in pazienti affetti da emofilia A o B, con anticorpi inibitori del fattore VIII o IX
- **Studio STASEY (MO39129):** A single-arm, multicenter phase IIIB clinical trial to evaluate the safety and tolerability of prophylactic Emicizumab in hemophilia A patients with inhibitors (Roche).
- **Studio Von:** Studio clinico di fase 3, prospettico, multicentrico, non controllato, in aperto, per determinare l'efficacia, la sicurezza e la tollerabilità di rVWF, con o senza ADVATE, nel trattamento e nel controllo di episodi emorragici, l'efficacia e la sicurezza di rVWF in procedure chirurgiche di elezione e di emergenza, e la farmacocinetica (PK) di rVWF in bambini con diagnosi di malattia di von Willebrand in forma grave (Shire). Approvato, nessun arruolamento.
- **Studio GUARDIAN-5 (NN7008-3553):** Studio osservazionale sull'utilizzo di Turoctocog alfa (rFVIII) nel trattamento a lungo termine dell'emofilia A (Novo Nordisk).
- **Studio 997HA306** An Open-Label, Multicenter Evaluation of the Safety and Efficacy of Recombinant Coagulation Factor VIII Fc Fusion Protein (rFVIII-Fc; BLIB031) in the Prevention and Treatment of Bleeding in Previously (Sobi)
- **Studio TAURUS:** A Multinational Phase IV Study Evaluating "Real World" Treatment Pattern in Previously Treated Hemophilia A Patients Receiving KOVALTRY (Octocog alfa) for Routine Prophylaxis (Bayer)
- **Studio IDEAL** Non Interventistico Retrospektivo e Prospettico per Valutare, nella Realtà Clinica, gli Aggiustamenti Posologici e gli Esiti Clinici conseguenti al trattamento con una Proteina ricombinante di fusione costituita dal fattore IX della coagulazione con albumina a Lunga Durata di Azione (rIX-FP, IDELVION®) in Pazienti affetti da Emofilia B (CSL Behring)
- **Studio GENA99.** Prospective, multinational, non-interventional post-authorisation study to document the long-term immunogenicity, safety, and efficacy of Human-cl rhFVIII (simoctocog alfa) in patients with haemophilia A treated in routine clinical practice (Kedrion).
- **Studio A-SURE** prospettico, multicentrico, non interventistico, della durata di 24 mesi per la valutazione dell'efficacia di Elocta rispetto a prodotti convenzionali contenenti fattori della coagulazione nel trattamento profilattico di pazienti affetti da emofilia A (Sobi).
- Studio FEIBA NF GLOBAL OUTCOME STUDY (**FEIBA-GO**) (Shire)
- **Studio AHEAD** Advate antihemophilic FVIII recombinant plasma albumin free
- Studio longitudinale (B1831081) non interventistico per valutare l'accettabilità e la soddisfazione dei pazienti con emofilia A trattati a domanda o in profilassi con il nuovo dispositivo di somministrazione **FUSENGO** del fattore VIII (Pfizer)
- Phase I/III Open-label, Multicenter, Crossover Safety, Efficacy and Pharmacokinetic Study (**CSL627**) of Recombinant Coagulation Factor VIII (rFVIII) Compared to Recombinant Human Anti-haemophilic Factor VIII (rFVIII; INN: octocog alfa) in Subjects with Hemophilia A, and a Repeat PK, Safety and Efficacy Study (CSL Behring)
- Willebrand International Non interventional Global Surveillance, **WINGS**, (Kedrion)
- Clinical study (**BI 1160.84**) to evaluate the safety and efficacy of Pradaxa® (dabigatran etexilate) in patients with moderate renal impairment (creatinine clearance of 30-50 ml/min) undergoing surgery for hip or knee replacement. International multicenter study. (Boehringer-Ingelheim)

- A phase 3, randomized, double-blind, double-dummy, parallel -group, multi-center, multi-national study for the evaluation of the efficacy and safety of (LMW) Heparin/Edoxaban versus (LMW) Heparin/Warfarin in subjects with symptomatic deep vein thrombosis and/or pulmonary embolism (**HOKUSAI-VTE**). International multi center study. (Daiichi Sankyo)
- Twice-daily oral direct thrombin inhibitor dabigatran in the long term prevention of recurrent symptomatic venous thromboembolism in patients with symptomatic deep-vein thrombosis or pulmonary embolism (**RE-SONATE**) International multi center study. International multicenter study. (Boehringer-Ingelheim)
- A phase III, randomised, multicenter, double-blind, parallel-group, active controlled study to evaluate the efficacy and safety of oral dabigatran etexilate (150 mg bid) thromboembolism (**RE-MEDY**, Secondary VTE prevention)". International multicenter study.. (Boehringer-Ingelheim)
- Venous thromboembolism in orthopedic surgery and traumatology of the shoulder: prospective multicenter registry study. (**RECOS**). (Bayer)
- Aspirin after six months or one year of oral anticoagulants for the prevention of recurrent venous thromboembolism and cardiovascular events in patients with idiopathic venous thromboembolism (**WARFASA**)" (Università di Perugia)
- Study: Prevalence of clones with paroxysmal nocturnal hemoglobinuria phenotype in patients with splenic thrombosis (Insubria University)
- A safety and efficacy trial evaluating the use of Apixaban for the extended treatment of deep vein thrombosis and pulmonary embolism. (**AMPLIFY-EXT**). (Pfizer/BMS)
- Study on application of an algorithm that incorporates both serial ultrasound assessment of deep venous system that the evaluation of D-dimer in a large consecutive series of patients with idiopathic proximal DVT can help identify a subgroup of patients with OAT can be suspended with reasonable assurance. (**MORGAGNI**) (University of Padova)
- Cerebral haemorrhage in haemophilia A, B and other rare congenital bleeding: epidemiology and therapy. Retrospective observational study. (University of Padova)
- Prospective observational study in patients treated with Haemate Haemate P and P at a reduced volume in the treatment of von Willebrand disease (**HAEMATE-P study**). (CSL Behring)
- Italian study of post-registration surveillance of ADVATE (rAHF-PFM) in Hemophilia A in order to assess the efficacy, safety and immunogenicity (**P.I.S.A.**). (Baxter)
- "A prospective observational registry on the use of Novoseven for on demand treatment of mild moderate bleeds in haemophilia A and B patients with inhibitors. Studio internazionale osservazionale multicentrico (**ONE-Registry**). (Novo Nordisk)
- Prophylactic treatment with recombinant FVII (rFVIIa, Novoseven): **PRO-PACT** (Novo Nordisk) Study monitoring post-authorization safety of patients in transition from ReFacto ReFacto AF or other products containing FVIII in the context of usual care (**ReFacto-AF study**) (Wyeth/Pfizer)
- Clinical and laboratory diagnosis of patients with vWD3: prevalence of antibodies against vWF (University of Milano)
- Study on treatment and management of patients with acquired haemophilia (**EACH2**). Retrospective observational study (University of Milano)
- Treatment of congenital FVII deficiency. A prospective observational study (**STER**). (Novo Nordisk)

- Efficacy, safety and pharmaco-economic assessment of secondary long term prophylaxis with highly purified, standardized, doubly virus inactivated FVIII/vWF concentrates in patients with severe, inherited vWD and frequent bleedings. (**PRO-WILL**). (Grifols)
- Observational study non-sponsored "The Sixty + Prospective Hemophilia Assessment Registry: prospective study on health status in haemophilia patients older than 60 years" (**S+PheRA**). (University of Perugia)
- Study to assess the pharmacokinetics of the formulation of rFIX BeneFIX in the Italian population of patients with severe and moderate haemophilia B previously treated. (**BENEPHIT**). (University of Firenze)
- A multinational trial evaluating safety and efficacy, including pharmacokinetics, of NN 0129-0000-1003 when administered for treatment and prophylaxis of bleeding in patients with haemophilia A (**PATHFINDER 2**) (Novo Nordisk)
- Efficacy and safety of NN 0129-0000-1003 during surgical procedures in patients with haemophilia A (**PATHFINDER 3**) (Novo Nordisk).

Registries:

- International Registry on the Symptomatic Hemophilia A/B Carriers: The Pink Color of Hemophilia (**ISTH/SSC**)
- "Registro italiano sull'uso di Morotocog-alfa per il regime di immunotolleranza in pazienti con emofilia ed inibitore" - **REFIT**
- Prevention of Thromboembolic Events - European Registry of Venous Thromboembolism - **PREFER in VTE**. (Daiichi Sankyo)
- "International Registry of patients with venous thromboembolism (**RIETE**)"
- Italian Registry of patient with haemorrhagic deficiencies (EMOWEB)
- Italian Registry of Splenic Venous Thrombosis
- Italian Registry of Cerebral Venous Thrombosis
- Italian Registry of Superficial Venous Thrombosis
- Italian Registry of Post Partum Haemorrhage
- Registro Italiano Emorragie Cerebrali (EMOREC)
- Registro Immunotolleranze con Refacto (REFIT)
- European Haemophilia safety Surveillance System (EHUASS)
- Registro Italiano PK-FXIII